CEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven primarily by hematology sales, and an adjusted EBITDA margin of 34%. He noted strong demand for Altuvoct and Vonjo, with Altuvoct ...

AstraZeneca reports mixed results in the fourth quarter. It gains in pre-market after assuring investors that the business ...

Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The French drugmaker said it had entered a mandate with an “investment service provider”, with the purchase occurring between ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased ...

Government faces healthcare crisis as new physician output drops significantly in Korea New challenges arise as disruptions in medical education threaten Koreas healthcare future.